LONDON--(BUSINESS WIRE)--The first public data on Ossulin™ a new oral insulin product, will be presented today at the 9th Annual Diabetes Technology Meeting in San Francisco, CA. Ossulin™ is being developed by Puredel Limited, a joint-venture between the European pharmaceutical specialty company CM&D Pharma Limited (www.cmdpharmaltd.com) and Natreon Inc., New Brunswick, NJ., developers of the proprietary delivery platform (www.natreoninc.com).
